{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:13:31Z","timestamp":1794572011493,"version":"4.9.1"},"reference-count":118,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Antiphospholipid syndrome (APS), more common than once believed, is an autoimmune disease best known for its high risk of incident and recurrent thrombotic events. The approach to treatment potentially differs from treatment of thrombosis in the general population, and this article endeavors to review the latest updates on this topic.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The epidemiology of APS is being increasingly elucidated by large population-based studies, with APS perhaps affecting as many as 1 in 2000 individuals. Vitamin K antagonists, aspirin, and heparinoids continue to have obvious roles in the management of patients with APS. There has recently been intensive study of direct oral anticoagulants in APS, with the most recent randomized studies raising concerns about their inferiority to vitamin K antagonists, at least in some subgroups. Other approaches to treating APS beyond anticoagulants and antiaggregants are also receiving increased attention in mechanistic and preclinical studies with an eye toward future roles in patients with refractory and\/or microvascular disease. Pediatric APS is identified as an area in desperate need of additional prospective research.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Progress continues to be made in pursuit of improving the lives of individuals afflicted with APS. The most important future directions would seem to involve leveraging modern molecular technologies in order to improve subphenotyping of antiphospholipid antibody-positive individuals. This will help personalize risk profiles and ideally define the optimal approach to therapy based on future risk, rather than past morbid events.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000702","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T22:17:13Z","timestamp":1584569833000},"page":"215-227","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of thrombotic antiphospholipid syndrome in adults and children"],"prefix":"10.1097","volume":"32","author":[{"given":"Jacqueline A.","family":"Madison","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine"},{"name":"Division of Pediatric Rheumatology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al\u00ed","family":"Duarte-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Mayo Clinic"},{"name":"Robert D. and Patricia E. Kern Center for the Science of Healthcare Delivery, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zuo","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Knight","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/asheducation-2013.1.675","article-title":"Antiphospholipid syndrome","volume":"2013","author":"Lim","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-3-319-55442-6_8","article-title":"Clinical and prognostic significance of noncriteria antiphospholipid antibody tests","author":"Bertolaccini","year":"2017","journal-title":"Antiphospholipid syndrome: current research highlights and clinical insights"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11926-015-0504-5","article-title":"Pediatric antiphospholipid syndrome","volume":"17","author":"Aguiar","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"e1100","DOI":"10.1542\/peds.2008-1209","article-title":"Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry","volume":"122","author":"Avcin","year":"2008","journal-title":"Pediatrics"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/art.40901","article-title":"The epidemiology of antiphospholipid syndrome: a population-based study","volume":"71","author":"Duarte-Garc\u00eda","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-0038-1648840","article-title":"Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects","volume":"72","author":"Vila","year":"1994","journal-title":"Thromb Haemost"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.exger.2004.08.003","article-title":"Antibeta 2 glycoprotein I antibodies in centenarians","volume":"39","author":"Meroni","year":"2004","journal-title":"Exp Gerontol"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"17103","DOI":"10.1038\/nrdp.2017.103","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Disease Primers"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"277","DOI":"10.7326\/M18-2130","article-title":"Antiphospholipid antibodies in patients with myocardial infarction","volume":"170","author":"Grosso","year":"2019","journal-title":"Ann Intern Med"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study","volume":"8","author":"Urbanus","year":"2009","journal-title":"Lancet Neurol"},{"key":"R12-20230829","article-title":"Prevalence of confirmed antiphospholipid syndrome in 18\u201350 years unselected patients with first unprovoked venous thromboembolism","author":"Miranda","year":"2019","journal-title":"J Thromb Haemost"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1177\/0961203316640912","article-title":"Systematic review of case reports of antiphospholipid syndrome following infection","volume":"25","author":"Abdel-Wahab","year":"2016","journal-title":"Lupus"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/00003246-200204000-00007","article-title":"Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions","volume":"30","author":"Wenzel","year":"2002","journal-title":"Crit Care Med"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jcrc.2014.02.005","article-title":"Antiphospholipid antibodies in critically ill patients with cancer: a prospective cohort study","volume":"29","author":"Vassalo","year":"2014","journal-title":"J Crit Care"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11926-010-0149-3","article-title":"Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?","volume":"13","author":"Barbhaiya","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.autrev.2017.09.003","article-title":"Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: pro's and con's","volume":"16","author":"Arnaud","year":"2017","journal-title":"Autoimmun Rev"},{"key":"R18-20230829","first-page":"223","article-title":"Prevention and treatment of thrombotic antiphospholipid syndrome","author":"Crowther","year":"2016","journal-title":"Antiphospholipid syndrome current research highlights and clinical insights"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/art.22663","article-title":"Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals","volume":"56","author":"Erkan","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/rheumatology\/41.8.924","article-title":"A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome","volume":"41","author":"Erkan","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"61","author":"Tektonidou","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/0961203307084724","article-title":"Influence of aspirin on the clinical outcomes of 103 antiphospholipid antibodies-positive patients","volume":"17","author":"Hereng","year":"2008","journal-title":"Lupus"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0140-6736(17)30770-5","article-title":"Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study","volume":"390","author":"Li","year":"2017","journal-title":"Lancet"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1055\/s-0028-1082271","article-title":"Pediatric antiphospholipid antibodies and antiphospholipid syndrome","volume":"34","author":"Hunt","year":"2008","journal-title":"Semin Thromb Hemost"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0090-1229(86)90046-2","article-title":"Anticardiolipin response in acute infections","volume":"41","author":"Vaarala","year":"1986","journal-title":"Clin Immunol Immunopathol"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1651-2227.2000.tb00733.x","article-title":"Lupus anticoagulant and protein S deficiency in otherwise healthy children with acute varicella infection","volume":"89","author":"Kurugol","year":"2000","journal-title":"Acta Paediatr"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0022-3476(96)70274-3","article-title":"Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis","volume":"128","author":"Manco-Johnson","year":"1996","journal-title":"J Pediatr"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/intimm\/dxf043","article-title":"Antibeta(2)-glycoprotein I antibodies in children with atopic dermatitis","volume":"14","author":"Ambrozic","year":"2002","journal-title":"Int Immunol"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1136\/annrheumdis-2016-211001","article-title":"European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R30-20230829","first-page":"e000924","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"5","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 1)","key":"R31-20230829","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1177\/10760296990050S112","article-title":"Long-term outpatient dalteparin (fragmin) therapy for arterial and venous thrombosis: efficacy and safety--a preliminary report","volume":"5","author":"Bick","year":"1999","journal-title":"Clin Appl Thromb Hemost"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1136\/ard.2011.150268","article-title":"Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome","volume":"70","author":"Vargas-Hitos","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R33-20230829","first-page":"35","article-title":"Low-molecular heparins in the treatment of APS-nephropathy in primary and secondary antiphospholipid syndrome","volume":"76","author":"Kozlovskaia","year":"2004","journal-title":"Ter Arkh"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J Med"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9343(98)00060-6","article-title":"Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group","volume":"104","author":"Schulman","year":"1998","journal-title":"Am J Med"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1182\/blood.V86.10.3685.bloodjournal86103685","article-title":"Antiphospholipid antibodies and venous thromboembolism","volume":"86","author":"Ginsberg","year":"1995","journal-title":"Blood"},{"key":"R38-20230829","first-page":"135","article-title":"Anticoagulation treatment withdrawal in primary antiphospholipid syndrome when anticardiolipin antibodies become negative","volume":"208","author":"Criado-Garcia","year":"2008","journal-title":"Rev Clin Esp"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12026-013-8407-x","article-title":"Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative","volume":"56","author":"Coloma Bazan","year":"2013","journal-title":"Immunol Res"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.autrev.2017.02.004","article-title":"Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: thrombosis recurrence","volume":"16","author":"Medina","year":"2017","journal-title":"Autoimmun Rev"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1161\/01.STR.29.11.2245","article-title":"Cerebrovascular ischemic events with high positive anticardiolipin antibodies","volume":"29","author":"Verro","year":"1998","journal-title":"Stroke"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.semarthrit.2016.02.002","article-title":"Rituximab usage in systemic lupus erythematosus-associated antiphospholipid syndrome: a single-center experience","volume":"46","author":"Wang","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R43-20230829","first-page":"15","article-title":"Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome","volume":"7","author":"Okuma","year":"2009","journal-title":"Int J Med Sci"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1001\/archinte.1997.00440390101013","article-title":"A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis","volume":"157","author":"Krnic-Barrie","year":"1997","journal-title":"Arch Intern Med"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/rheumatology\/key340","article-title":"Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome","volume":"58","author":"Ohnishi","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016\u200aACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R48-20230829","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1055\/s-0039-1692702","article-title":"Cardiac manifestations of antiphospholipid syndrome: clinical presentation, role of cardiac imaging, and treatment strategies","volume":"45","author":"Tufano","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"R49-20230829","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.autrev.2014.11.003","article-title":"Antiphospholipid syndrome and the heart: a case series and literature review","volume":"14","author":"Denas","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, noninferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"R52-20230829","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"R53-20230829","doi-asserted-by":"crossref","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"R54-20230829","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0961203319889156","article-title":"Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study","volume":"29","author":"Malec","year":"2020","journal-title":"Lupus"},{"key":"R55-20230829","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.clinthera.2019.06.015","article-title":"Recurrent thrombosis with direct oral anticoagulants in antiphospholipid syndrome: a systematic literature review and meta-analysis","volume":"41","author":"Sanchez-Redondo","year":"2019","journal-title":"Clin Ther"},{"key":"R56-20230829","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.autrev.2018.04.009","article-title":"Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis","volume":"17","author":"Dufrost","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R57-20230829","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/MBC.0000000000000576","article-title":"A retrospective review of pediatric antiphospholipid syndrome and thrombosis outcomes","volume":"28","author":"Nageswara Rao","year":"2017","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R58-20230829","first-page":"1428","article-title":"Cerebral infarction and antiphospholipid syndrome in children","volume":"23","author":"Baca","year":"1996","journal-title":"J Rheumatol"},{"key":"R59-20230829","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s10067-017-3776-5","article-title":"Clinical characteristics and thrombosis outcomes of paediatric antiphospholipid syndrome: analysis of 58 patients","volume":"37","author":"Ma","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"(Suppl 10)","key":"R60-20230829","article-title":"Development of new international classification criteria for antiphospholipid syndrome: phase II results [abstract]","volume":"71","author":"Barbhaiya","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R61-20230829","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/hematology.2019000073","article-title":"Is there a role for immunosuppression in antiphospholipid syndrome?","volume":"2019","author":"Sevim","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R62-20230829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review","volume":"92","author":"Cervera","year":"2018","journal-title":"J Autoimmun"},{"key":"R63-20230829","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/BOR.0000000000000269","article-title":"Treatment of catastrophic antiphospholipid syndrome","volume":"28","author":"Kazzaz","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"R64-20230829","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10238-019-00565-8","article-title":"Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature","volume":"19","author":"Tinti","year":"2019","journal-title":"Clin Exp Med"},{"key":"R65-20230829","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature","volume":"49","author":"Kello","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R66-20230829","first-page":"346","article-title":"The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus","volume":"34","author":"Bayraktar","year":"2007","journal-title":"J Rheumatol"},{"key":"R67-20230829","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.autrev.2013.10.004","article-title":"Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the \u2018CAPS Registry\u2019","volume":"13","author":"Berman","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R68-20230829","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/BOR.0000000000000426","article-title":"The catastrophic antiphospholipid syndrome in children","volume":"29","author":"Go","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"R69-20230829","first-page":"174","article-title":"Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty","volume":"144","author":"Johnson","year":"1979","journal-title":"Clin Orthopaed Relat Res"},{"key":"R70-20230829","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1161\/01.CIR.96.12.4380","article-title":"Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice","volume":"96","author":"Edwards","year":"1997","journal-title":"Circulation"},{"key":"R71-20230829","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood-2008-03-144204","article-title":"Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers","volume":"112","author":"Rand","year":"2008","journal-title":"Blood"},{"key":"R72-20230829","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2009-04-213520","article-title":"Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug","volume":"115","author":"Rand","year":"2010","journal-title":"Blood"},{"key":"R73-20230829","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12026-016-8812-z","article-title":"Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome","volume":"65","author":"Nuri","year":"2017","journal-title":"Immunol Res"},{"key":"R74-20230829","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3899\/jrheum.120157","article-title":"Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and\/or lupus anticoagulant in systemic lupus erythematosus","volume":"40","author":"Broder","year":"2013","journal-title":"J Rheumatol"},{"key":"R75-20230829","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/ard.2008.093013","article-title":"Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multiethnic cohort","volume":"68","author":"Kaiser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R76-20230829","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"15","author":"Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"key":"R77-20230829","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/0961203317724219","article-title":"Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease","volume":"27","author":"Erkan","year":"2018","journal-title":"Lupus"},{"key":"R78-20230829","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/jth.12363","article-title":"Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients","volume":"11","author":"Schmidt-Tanguy","year":"2013","journal-title":"J Thromb haemost"},{"key":"R79-20230829","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.autrev.2014.01.053","article-title":"14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends","volume":"13","author":"Erkan","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R80-20230829","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R81-20230829","first-page":"139","article-title":"Immunomodulatory effects of HMG-CoA reductase inhibitors","volume":"51","author":"Danesh","year":"2003","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"R82-20230829","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/imm.12902","article-title":"Immune modulatory effects of statins","volume":"154","author":"Zeiser","year":"2018","journal-title":"Immunology"},{"key":"R83-20230829","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1002\/art.11449","article-title":"Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model","volume":"48","author":"Ferrara","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R84-20230829","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/ard.2010.135525","article-title":"Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome","volume":"70","author":"Lopez-Pedrera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R85-20230829","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/annrheumdis-2013-203622","article-title":"A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients","volume":"73","author":"Erkan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R86-20230829","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1177\/0961203318772015","article-title":"Simvastatin reduces antiphospholipid antibodies formation in patients with systemic lupus erythematosus: a preliminary study","volume":"27","author":"Kotyla","year":"2018","journal-title":"Lupus"},{"key":"R87-20230829","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/0961203317716787","article-title":"Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies","volume":"27","author":"Watanabe","year":"2018","journal-title":"Lupus"},{"key":"R88-20230829","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet (London, England)"},{"key":"R89-20230829","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/RHU.0b013e31818f38d4","article-title":"Clinical improvement in antiphospholipid syndrome after rituximab therapy","volume":"14","author":"Adamson","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"R90-20230829","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for noncriteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R91-20230829","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/acr.22109","article-title":"Primary antiphospholipid syndrome-associated diffuse alveolar hemorrhage","volume":"66","author":"Cartin-Ceba","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R92-20230829","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"key":"R93-20230829","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1136\/annrheumdis-2018-213496","article-title":"Anticardiolipin and antibeta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab","volume":"77","author":"Sciascia","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R94-20230829","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/0961203316682102","article-title":"Belimumab in primary antiphospholipid syndrome","volume":"26","author":"Yazici","year":"2017","journal-title":"Lupus"},{"key":"R95-20230829","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.200116116","article-title":"Complement C3 activation is required for antiphospholipid antibody-induced fetal loss","volume":"195","author":"Holers","year":"2002","journal-title":"J Exp Med"},{"key":"R96-20230829","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/art.21157","article-title":"Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia","volume":"52","author":"Pierangeli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R97-20230829","first-page":"455","article-title":"Antiphospholipid antibodies and complement activation in patients with cerebral ischemia","volume":"10","author":"Davis","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"R98-20230829","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood.V100.2.517","article-title":"C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils","volume":"100","author":"Wojta","year":"2002","journal-title":"Blood"},{"key":"R99-20230829","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"New Engl J Med"},{"key":"R100-20230829","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"New Engl J Med"},{"key":"R101-20230829","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"New Engl J Med"},{"key":"R102-20230829","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/ajt.12319","article-title":"Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes","volume":"13","author":"Canaud","year":"2013","journal-title":"Am J Transplant"},{"key":"R103-20230829","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ajt.12540","article-title":"Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation","volume":"14","author":"Lonze","year":"2014","journal-title":"Am J Transplant"},{"key":"R104-20230829","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R105-20230829","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2741\/4231","article-title":"Clinical applications of coenzyme Q10","volume":"19","author":"Garrido-Maraver","year":"2014","journal-title":"Front Biosci (Landmark Ed)"},{"key":"R106-20230829","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1161\/ATVBAHA.117.309225","article-title":"Ubiquinol effects on antiphospholipid syndrome prothrombotic profile: a randomized, placebo-controlled trial","volume":"37","author":"Perez-Sanchez","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R107-20230829","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/art.39247","article-title":"Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome","volume":"67","author":"Yalavarthi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R108-20230829","article-title":"Increased adhesive potential of antiphospholipid syndrome neutrophils mediated by beta-2 integrin Mac-1","author":"Sule","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R109-20230829","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/art.39938","article-title":"In vivo role of neutrophil extracellular traps in antiphospholipid antibody-mediated venous thrombosis","volume":"69","author":"Meng","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R110-20230829","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93897","article-title":"Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target","volume":"2","author":"Knight","year":"2017","journal-title":"JCI Insight"},{"key":"R111-20230829","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1128\/IAI.02487-14","article-title":"Cyclic AMP-mediated suppression of neutrophil extracellular trap formation and apoptosis by the Bordetella pertussis adenylate cyclase toxin","volume":"82","author":"Eby","year":"2014","journal-title":"Infect Immun"},{"key":"R112-20230829","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bph.13373","article-title":"Prostaglandin E2 inhibits neutrophil extracellular trap formation through production of cyclic AMP","volume":"173","author":"Shishikura","year":"2016","journal-title":"Br J Pharmacol"},{"key":"R113-20230829","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41467-019-09801-x","article-title":"Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome","volume":"10","author":"Ali","year":"2019","journal-title":"Nat Commun"},{"key":"R114-20230829","first-page":"2006","article-title":"Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator","volume":"29","author":"Burcoglu-O\u2019Ral","year":"2002","journal-title":"J Rheumatol"},{"key":"R115-20230829","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1182\/blood-2004-01-0145","article-title":"Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep","volume":"104","author":"Zhou","year":"2004","journal-title":"Blood"},{"key":"R116-20230829","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/jth.14427","article-title":"Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation","volume":"17","author":"Hisada","year":"2019","journal-title":"J Thromb Haemost"},{"key":"R117-20230829","doi-asserted-by":"crossref","first-page":"102311","DOI":"10.1016\/j.jaut.2019.102311","article-title":"Type I interferon gene expression in antiphospholipid syndrome: pathogenetic, clinical and therapeutic implications","volume":"104","author":"Xourgia","year":"2019","journal-title":"J Autoimmun"},{"key":"R118-20230829","doi-asserted-by":"crossref","first-page":"108265","DOI":"10.1016\/j.clim.2019.108265","article-title":"Independent association of low IFNlambda1 gene expression and type I IFN score\/IFNlambda1 ratio with obstetric manifestations and triple antiphospholipid antibody positivity in primary antiphospholipid syndrome","volume":"209","author":"Flessa","year":"2019","journal-title":"Clin Immunol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T07:12:23Z","timestamp":1693293143000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":118,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000702","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}